Cephalic Phase in Anorexia Nervosa,Bulimia Nervosa and Obese Binge Eaters (Cephalic 1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00493519|
Recruitment Status : Unknown
Verified April 2007 by Tel-Aviv Sourasky Medical Center.
Recruitment status was: Recruiting
First Posted : June 28, 2007
Last Update Posted : July 6, 2007
|Condition or disease||Intervention/treatment||Phase|
|Anorexia Nervosa Bulimia Nervosa||Procedure: chocolate cake||Not Applicable|
Food stimulation of gastric and pancreatic secretion is classically divided into cephalic, gastric and intestinal phases.
Cephalic phase refers to a simultaneous activation of gastrointestinal motility, gastric acid and pancreatic enzyme secretion ,as well as, release of hormones from the endocrine pancreas which occurs through activation of vagal -efferents as a result of food-related sensory stimuli such as taste and smell prior to nutrient absorption and which coincides with a thermogenic response.
Of the cephalic phase secretions, cephalic phase insulin release (CPIR) has received the most attention, but pancreatic polypeptide (PP) and glucagon responses have also been studied. While the magnitude of cephalic phase insulin release is relatively small (25% above baseline), pancreatic polypeptide increases 100% above baseline. The large magnitude of the PP response makes it a sensitive indicator of vagal activation to food stimuli.
In most experiments, subjects are either exposed to visual and olfactory stimulation by seeing and smelling the food stimulus or are required to perform a modified sham-feed, i.e. to taste, chew and then expectorate the food stimulus.
In general, cephalic phase are thought to be preparatory response before ingestion of food. Because of their small magnitude, the physiological significance of the cephalic phase hormonal responses has been largely discounted. However, there is evidence that experimental prevention of CPIR lead to hyperinsulinemia and hyperglycemia. Therefore, CPIR may contribute to glucose homeostasis /regulation. Moreover CPIR may be an indicator of hunger and could be important for understanding eating disorders.
In parallel with these hormonal secretion ,an increase in energy expenditure has also been observed . This thermogenic response to food is even greater with sham feeding than with normal feeding and is paralleled by changes in RQ showing enhanced carbohydrate oxidation.
Studies conducted in obese humans demonstrate exaggerated absolute magnitude of CPIR .However basal hyper-insulinemia which is typically observed in obese individuals may clouds this observation. Moreover, it has been hypothesized that CPIR is attenuated in obese when is expressed as a percentage of baseline and therefore they may not secrete enough insulin during pre-absorptive period to regulate postprandial glucose levels.
There is also evidence that obese people with insulin resistance have a reduced thermogenic response to feeding .
Only limited numbers of studies have been done on the cephalic phase in anorexia and bulimia. There are findings of a significant CPIR in anorexics as compared to controls which tends to rule out a deficient cephalic insulin response as a contributor to the self-starvation observed in anorexia nervosa. As to bulimics who often show endocrine abnormalities, their CPIR was only slightly differ or from controls.
These findings suggest more complex determinants of eating disorders than physiological state alone.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||75 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Cephalic Phase in Anorexia Nervosa,Bulimia Nervosa and Obese Binge Eaters|
|Study Start Date :||July 2007|
|Estimated Study Completion Date :||December 2007|
- VAS, EDI, Blood test for glucose, insulin, PP, shame feed procedure [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00493519
|Contact: Nachum Vaisman, Prof.||+email@example.com|
|Tel Aviv, Israel, 64239|
|Contact: Nachum Vaisman, Prof. +972-524-266596 firstname.lastname@example.org|
|Principal Investigator:||Nachum Vaisman, Prof.||TASMC Israel|